Caption Management LLC Invests $1.74 Million in ICU Medical, Inc. $ICUI

Caption Management LLC bought a new position in ICU Medical, Inc. (NASDAQ:ICUI) during the 1st quarter, Holdings Channel.com reports. The institutional investor bought 12,510 shares of the medical instruments supplier’s stock, valued at approximately $1,737,000.

A number of other institutional investors have also recently bought and sold shares of the stock. Tower Research Capital LLC TRC boosted its holdings in shares of ICU Medical by 87.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,352 shares of the medical instruments supplier’s stock valued at $210,000 after purchasing an additional 632 shares during the last quarter. Hsbc Holdings PLC increased its holdings in shares of ICU Medical by 12.1% during the 4th quarter. Hsbc Holdings PLC now owns 5,707 shares of the medical instruments supplier’s stock worth $886,000 after buying an additional 618 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of ICU Medical by 17.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 17,772 shares of the medical instruments supplier’s stock worth $2,758,000 after buying an additional 2,578 shares during the period. Quarry LP boosted its holdings in ICU Medical by 764.3% in the fourth quarter. Quarry LP now owns 242 shares of the medical instruments supplier’s stock valued at $38,000 after acquiring an additional 214 shares during the last quarter. Finally, Northern Trust Corp boosted its holdings in ICU Medical by 11.1% in the fourth quarter. Northern Trust Corp now owns 402,342 shares of the medical instruments supplier’s stock valued at $62,431,000 after acquiring an additional 40,187 shares during the last quarter. 96.10% of the stock is currently owned by hedge funds and other institutional investors.

ICU Medical Price Performance

ICUI stock opened at $127.66 on Monday. The stock has a 50-day simple moving average of $126.87 and a 200-day simple moving average of $135.64. The firm has a market cap of $3.15 billion, a P/E ratio of -83.99 and a beta of 0.86. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.17 and a current ratio of 2.44. ICU Medical, Inc. has a 1 year low of $107.00 and a 1 year high of $196.26.

ICU Medical (NASDAQ:ICUI) last released its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $2.10 earnings per share for the quarter, topping analysts’ consensus estimates of $1.44 by $0.66. ICU Medical had a positive return on equity of 7.24% and a negative net margin of 1.56%.The firm had revenue of $543.57 million during the quarter, compared to analysts’ expectations of $543.33 million. During the same quarter in the prior year, the business earned $1.56 EPS. ICU Medical’s quarterly revenue was down 8.0% compared to the same quarter last year. ICU Medical has set its FY 2025 guidance at 6.850-7.15 EPS. On average, equities analysts predict that ICU Medical, Inc. will post 4.11 earnings per share for the current fiscal year.

Insider Buying and Selling at ICU Medical

In other news, Director David C. Greenberg purchased 1,200 shares of the stock in a transaction that occurred on Wednesday, August 27th. The stock was acquired at an average cost of $126.42 per share, with a total value of $151,704.00. Following the acquisition, the director owned 7,960 shares in the company, valued at approximately $1,006,303.20. This trade represents a 17.75% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Vivek Jain purchased 21,929 shares of the company’s stock in a transaction that occurred on Thursday, August 14th. The shares were purchased at an average cost of $112.84 per share, for a total transaction of $2,474,468.36. Following the purchase, the chief executive officer directly owned 130,149 shares in the company, valued at $14,686,013.16. This trade represents a 20.26% increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.50% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have commented on ICUI shares. Wall Street Zen lowered ICU Medical from a “buy” rating to a “hold” rating in a research note on Saturday, August 9th. Raymond James Financial decreased their target price on ICU Medical from $187.00 to $180.00 and set a “strong-buy” rating for the company in a report on Friday, August 8th. Finally, Piper Sandler assumed coverage on shares of ICU Medical in a report on Friday, August 15th. They issued an “overweight” rating and a $145.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $179.00.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.